Company news

Shanghai Henlius Biotech, Inc. news in 2025

Shanghai Henlius Biotech, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026

December 23, 2025

Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer

November 20, 2025

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

November 17, 2025

Forlong Biotechology Announces Collaboration Agreement with Henlius to Develop Innovative Cancer Immunotherapy with an Engineered Cytokine

October 22, 2025

Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission

October 9, 2025

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

September 19, 2025

FUTUONING Sets Sail Commercially with First Prescriptions Across China

September 5, 2025

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

September 2, 2025

Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach

August 25, 2025

HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach

July 1, 2025

Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar

April 29, 2025

Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights

April 17, 2025

Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report

April 16, 2025

Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY

March 24, 2025

Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer

March 19, 2025

FDA Accepts BLA For Shanghai Henlius Biotech's HLX11, A Pertuzumab Biosimilar

February 11, 2025

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

February 6, 2025

Shanghai Henlius Biotech, Inc. - US FDA Accepts Biologics License Application for HLX11, Biosimilar Candidate of Perjeta

February 3, 2025

Decks in 2025